Baxter International (BAX) Projected to Post Quarterly Earnings on Thursday

Baxter International (NYSE:BAX) is expected to be issuing its Q3 2025 results before the market opens on Thursday, October 30th. Analysts expect the company to announce earnings of $0.60 per share and revenue of $2.8774 billion for the quarter. Baxter International has set its Q3 2025 guidance at 0.580-0.620 EPS. FY 2025 guidance at 2.420-2.520 EPS.Investors are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Thursday, October 30, 2025 at 8:30 AM ET.

Baxter International (NYSE:BAX) last announced its quarterly earnings data on Thursday, July 31st. The medical instruments supplier reported $0.59 EPS for the quarter, missing the consensus estimate of $0.60 by ($0.01). The firm had revenue of $2.81 billion for the quarter, compared to analysts’ expectations of $2.82 billion. Baxter International had a negative net margin of 1.42% and a positive return on equity of 16.96%. The business’s quarterly revenue was up 4.3% compared to the same quarter last year. During the same period in the prior year, the business posted $0.68 EPS. On average, analysts expect Baxter International to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Baxter International Stock Up 0.7%

NYSE:BAX opened at $22.92 on Thursday. The company has a debt-to-equity ratio of 1.30, a current ratio of 2.30 and a quick ratio of 1.49. The firm’s 50-day moving average price is $23.49 and its 200-day moving average price is $27.21. The company has a market capitalization of $11.77 billion, a PE ratio of -76.38, a P/E/G ratio of 0.74 and a beta of 0.58. Baxter International has a 1-year low of $21.33 and a 1-year high of $37.74.

Institutional Investors Weigh In On Baxter International

Several large investors have recently bought and sold shares of the business. MUFG Securities EMEA plc purchased a new position in Baxter International in the 2nd quarter worth about $46,000. BI Asset Management Fondsmaeglerselskab A S grew its stake in shares of Baxter International by 21.4% in the second quarter. BI Asset Management Fondsmaeglerselskab A S now owns 24,356 shares of the medical instruments supplier’s stock worth $737,000 after acquiring an additional 4,293 shares during the period. Baird Financial Group Inc. grew its stake in shares of Baxter International by 3.2% in the second quarter. Baird Financial Group Inc. now owns 52,436 shares of the medical instruments supplier’s stock worth $1,588,000 after acquiring an additional 1,604 shares during the period. Captrust Financial Advisors raised its holdings in shares of Baxter International by 5.5% during the second quarter. Captrust Financial Advisors now owns 53,933 shares of the medical instruments supplier’s stock valued at $1,633,000 after purchasing an additional 2,813 shares during the last quarter. Finally, California State Teachers Retirement System lifted its position in Baxter International by 2.9% during the second quarter. California State Teachers Retirement System now owns 649,463 shares of the medical instruments supplier’s stock valued at $19,666,000 after purchasing an additional 18,439 shares during the period. 90.19% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. Evercore ISI decreased their target price on shares of Baxter International from $33.00 to $31.00 and set an “outperform” rating for the company in a research note on Tuesday, October 7th. UBS Group reduced their price objective on Baxter International from $35.00 to $24.00 and set a “neutral” rating for the company in a research report on Monday, August 4th. The Goldman Sachs Group downgraded Baxter International from a “buy” rating to a “neutral” rating and set a $25.00 target price on the stock. in a report on Friday, August 1st. Wall Street Zen downgraded Baxter International from a “buy” rating to a “hold” rating in a report on Saturday, August 2nd. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Baxter International in a research report on Wednesday, October 8th. Three equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $28.89.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.